A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 14, 2022

Primary Completion Date

September 4, 2023

Study Completion Date

September 4, 2023

Conditions
Lupus Erythematosus, Systemic
Interventions
DRUG

E6742

E6742 tablet.

OTHER

Placebo

E6742-matching placebo tablet.

Trial Locations (12)

Unknown

Chukyo Hospital, Nagoya

Daido Clinic, Nagoya

Matsuyama Red Cross Hospital, Matsuyama

Hospital of the University of Occupational and Environmental Health, Kitakyushu

Hokkaido University Hospital, Sapporo

Tohoku University Hospital, Sendai

Osaka University Hospital, Suita

Juntendo University Hospital, Bunkyo-ku

St. Luke's International Hospital, Chuo-ku

Tokyo Metropolitan Hospital Organization Tokyo Metropolitan Tama Medical Center, Fuchū

Center Hospital of the National Center for Global Health and Medicine, Shinjuku-ku

National Hospital Organization Kyushu Medical Center, Fukuoka

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY